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The plasma drug disposition, tissue residue levels and drug mass balance of flumequine we re studied 
in broilers following drinking water medication of flumequine (mean dosage 9.3 mg/kg b.w./day) with 
or without co-medication of sodium salicylale at two levels (31 .5 and 265 mg/kg b.w./day) during 8 
consecutive days. A steady state flumequine plasma concentration of approximate 0.9 ,ug/ml was 
obtained within one day atter start of medication. lts 7-hydroxy metabolite plasma concentration was 
a bout 1 0 % of the parent drug. Aft er cessation of flumequine medication its mean plasma depletion 
half-life was about 5.5 h. The flumequine pharmacokinetics was not affected by the sodium salicylale 
co-medication. Co-medication of sodium salicylale decreased the flumequine distribution into the 
muscle and the extent of its hydroxylation in liver and kidney. 
At 24 h hours atter cessation of medication the mean flumequine concentrations in muscle, liver, fat, 
skin and plasma we re below 0.1 0 ,ug/g or mi. At 24 h aft er medication traces of 7 -hydroxyflumequine 
could be quantified in kidney and liver. 
At 2 hours atter cessation of medication, sodium salicylale residues could be detected in kidney, liver 
and muscle (but not in fat and skin) of the broilers medicated at 265 mg/kg/day co-medication. At 24 
h after cessation of medication no salicylale residues could be quantified in kidney, liver and muscle 
(quantification limit 0.6 to 2 ,ug/g}. 
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The tissue data and the flumequine mass balance showed that no glucuronide or sulfata conjugates 
of flumequine were formed in broilers and that the main metabolite detected in faeces was 7-hydroxy-
flumequine; about 70 % of the flumequine administered to broilers could not be accounted. The 
plasma sodium salicylale data and the mass balance (total drug recovery 84.4%} pointed out, that 
sodium salicylate was oxidised into gentisic acid and no glucuronide or sulfata metabolites were 
formed. 
Keywords: flumequine, sodium salicylate, pharmacokinetics, residues, drug interaction, drug mass 
balance, screening methods. 
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SUMMARY 
The plasma drug disposition, tissue residue levels and drug mass balance of flumequine were studied 
in broilers following drinking water medicatien of flumequine (mean dosage 9.3 mg/kg b.w./day) with 
or without co-medication of sodium salicylate at two levels {31.5 and 265 mg/kg b.w./day) during 8 
consecutive days. A steady state flumequine plasma concentratien of approximate 0.9 .ug/ml was 
obtained within one day after start of medication. After cessation of flumequine medicatien its mean 
depletion half-life was about 5.5 h. The tlumequine plasma pharmacokinetics was not aftected by the 
sodium salicylate co-medication. 
At 2 hours after cessation of medication, the highest flumequine residue concentrations were found 
in the kidney (mean concentratien range 1.25 to 2.12 .ug/g), foliowed by liver, plasma, muscle (mean 
concentratien range: 0.16- 0.69 .ug/g), skin and fat in decreasing order of concentration. lts 7-hydroxy 
metabolite concentration was a lso the highest in kidney (mean concentratien range: 0.57- 0. 72 .ug/g), 
foliowed by skin, liver and plasma (about 10% of the parent drug). In muscle tissue the 7-
hydroxyflumequine concentratien was less than 6% of the parent drug and in fat tissue it was not 
quantifiable ( < 0.01 .ug/g). 
At 24 h hours after cessation of medication, flumequine residues could be quantified in 3 out of 16 
kidneys. At that time the mean flumequine concentrations in muscle, liver, fat, skin and plasma were 
below 0.1 0 .ug/g or mi. At 24 h aft er medicatien traces of 7 -hydroxyflumequine could be quantified in 
kidney and liver. A discrepancy between tissue concentratien data determined by bioassay versus 
HPLC was found tor kidney, liverand muscle (being higher in the bioassay), while tor plasmaand skin 
a good agreement was observed. 
Co-medication of sodium salicylate decreased the flumequine distribution into the muscle and its 
hydroxylation in liver and kidney. 
At 2 hours after cessation of medication, sodium salicylate residues could be detected in kidney, liver 
and muscle {but not in fat and skin) of the broilers medicated at 265 mg/kg/day co-medication. At 24 
hafter cessation of medicatien no salicylate residues could be quantified in kidney, liverand muscle 
(quantification limit 0.6 to 2 .ug/g). 
The tissue data and the flumequine mass balance showed that no glucuronide or sulfate conjugates 
of flumequine were formed in broilers and that the main metabolite detected in faeces was 7-hydroxy-
flumequine. However about 70 % of the flumequine administered to broilers could not be accounted. 
The plasma sodium salicylate data and the mass balance (total drug recovery 84.4%) pointed out, that 
sodium salicylate was oxidised into gentisic acid and no glucuronide or sullate metabolites were 
[Bformed. 
When kidney or liver are used as target tissue tor flumequine residue screening, negative results of 
an Escherichia co/i test plate indicate that the flumequine concentratien in muscle tissue is below the 
level of 0.1 0 or 0.20 .ug/g tissue, respectively 
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1 INTRODUCTION 
Flumequine is widely used in broilers tor the treatment and prevention of Escherichia co/i (colibacillosis 
complicated with airsacculitis), Haemophilus (lnfectious coryza), Salmonella and Pasteure/la multocida 
intections (2,6,7,1 0). Flumequine is a 6-fluorinated piperazinyl quinolone and following oral 
administration to calves, man and peultry it is tast and almost completely absorbed trom the gastro-
intestinal tract (1,2,20,29). The bioavailability of orally administered flumequine to poultry is 71.6% (2). 
Following a single oral dose to chickens the maximal flumequine plasma concentrations are obtained 
at about 2 h (2,6). The drug is diftused rapidly and well into the body (2,25) and the elimination half-
life after intravenous administration is 4.9 h (2). The highest drug concentrations after oral 
administration were found in kidney, spleen, liver and muscle (2) and at 36 hours after cessation of 
oral medication, residues could be detected in edible tissues of laying hens (25), but not in broilers 
(2). 
The main metabolic pathway in man (29) and calves (20) is glucuronidation of flumequine itself (phase 
11 conjugation reaction) and toa lesser extent, hydroxylation (phase I reaction) to 7-hydroxy-flumequine 
(fig. 1). In various fish species no metabolites of flumequine could be detected in plasma and tissues 
(3,11, 12), whereas in poultry the metabolism is unknown. In mammals flumequine, its glucuronide and 
its 7-hydroxy metabolite are excreted via renal and biliary route of elimination (20,29). 
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Fig. 1 Structures of f/umequine and its acylg/ucuronide metabolite. 
Flumequine can be hydroxy/ated into 7-hydroxyf/umequine. 
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Salicylic acid, released trom its precursor acetylsalicylic acid, is widely used in man and animals tor 
its analgesie and antipyretic effects (8, 14,27,28). Salicylic acid is a known inhibitor of prostaglandin 
(PG) production. Depressed PG levels may be beneficia! in disease proteetion (against E. coli 
infections) especially if it is combined with vitamin E in the diet (17). Another (side-)effect of decreased 
prostaglandin E production due to a dietary salicylic acid supplementation might be a decreased 
lipogenesis (14), but this reaction could not be confirmed in broilers (4, 18). In fast-growing broilers 
sodium salicylate is empirically used at a dose level of 50 mg/kg/day tor prevention of stress/pain (and 
lower feed intake) caused by locomotion disorders. At high dose levels (0.4 % in a diet) acetylsalicylic 
acid may led to poorer feed efficiency, increased mortality and in laying-hens it may induce smaller 
eggs and poorer eggshell quality (19). 
Salicylic acid (SA) can be conjugated (phase 11 reaction) with glycine, forming salicyluric acid (SU). 
Conjugation of SA and SU with glucuronic acid (phase 11 reaction) can take place at the tree phenolic 
hydroxy group leading to salicylic acid phenolic glucuronide (SAPG) or salicyluric acid phenolic 
glucuronide (SUPG), and, in case of SA, at the carboxyl group leading to salicylic acid acyl 
glucuronide (SAAG). The third way of metabolism occurs through oxidation (phase I reaction) to 2,5-
dihydroxy-benzoic acid (gentisic acid; GA) (14,24,26,27,31). Fig. 2 shows the metabolic pathways of 
salicylic acid and the possible metabolites. The major metabolite in most species (man, cattle, goat) 
is SU (8,13,24,28,30,31), whereas in the rat and rabbit SA is mainly excreted as parent drug 
(24,27,32). The metabolism of SA in poultry is unknown. 
Because of the possibility, that flumequine as well as salicylic acid may be metabolised extensively 
in poultry, a drug interaction in case of co-medication may occur in this species influencing their 
pharmacokinetics and tissue residue depletion. 
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Fig. 2 Metabolic pathway of sa/icylic acid (Vree et al., 1993). 
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2 OBJEeTIVES 
A comprehensive study was initialed with the following objectives: 
- to study plasma disposition of flumequine, salicylic acid (SA) and their metabolites in broilers 
following water medication during 8 consecutive days. 
- to study tissue distribution of flumequine, SA and their metabolites. 
- to study drug interactions with respect to tissue distribution and residue persistenee in case of co-
medication of flumequine and SA being the latter administered at two different dose levels. 
- to evaluate a microbiological screening methad tor the detection of flumequine residues in various 
matrices trom chickens. 
3 ANIMALS AND HOUSING 
3.1 Animals 
Thirty-six broilers (Ross strain; age 6 weeks; average body weight 2.6 kg; bath sexes equally divided) 
were used in this study. The broilers were individually identified by a coloured leg-ring. 
3.2 Housing 
The broilers were housed in three-tier battery cages in a climatized room at the Spelderholt Poultry 
Research eentre (Beekbergen, the Netherlands). The temperature intheroom was 22 oe tor the first 
day of medication and thereafter reset to 18 oe . The broilers had light tor 23 hours per day and the 
humidity was maintained at 55-70 %. 
The 36 broilers were divided at random into 3 groups of 12 broilers (equally sexed) and subsequently 
each group was equally subdivided over two cages (3 males and 3 females/cage). Each cage had 
separate drinking water and feed supplies. The faeces of each cage were separately collected on a 
stainless steel plate. The broilers received specially prepared feed without food additives, coccidiasta-
tics or growth promoters. 
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4 EXPERIMENTAL DESIGN 
4.1 Drugs 
Flumequine was obtained trom Sigma Chemieals (St. Louis, USA) and 7-hydroxyflumequine trom 
Riker/3M (Zoeterwoude, the Netherlands). Sodium salicylale was obtained trom De Onderlinge 
Pharmaceutische Groothandel (OPG, Utrecht, Netherlands), salicyluric acid trom Merck-Schuchardt 
(Hohenbrunn near Munich, Germany) and gentisic acid trom Janssen Chimica (Beerse, Belgium). 
4.2 Drug administration 
The broilers received medicated drinking water tor 8 consecutive days. 
The intended medication was as follows: 
Group A (n= 12; cage 1 and 2): 100 mg flumequine/litre water. 
Group 8 (n= 12; cage 3 and 4): 100 mg flumequine + 250 mg sodium salicylate/litre tap water. 
Group C (n= 12; cage 5 and 6): 100 mg flumequine + 1250 mg sodium salicylate/litre water. 
The medicated water was contained in a separate starage tank tor each cage and it was replaced 
once daily. The water consumption of each cage was determined daily by measuring remaining water 
volumes after the 24-hours-period. This was done until the end of medication. Water samples were 
taken just befare (24-h sample) and immediately after refreshment of the medicated water. At the end 
of the treatment period, the drinking water was replaced by drug-tree water and the water equipment 
was thoroughly flushad to remave drug residuals trom the system. 
4.3 Blood sampling 
Heparinised blood samples were taken by veni-puncture of the wing vein befare (0) and at 3, 6, 27, 
51, 75, 147, 171 h atter start of the medication. Blood sampling was also performed of the broilers in 
cage 1 , 3 and 5 at 3.5 and 6 h aft er cessation of the medication. The blood was centrifuged at 3000 
rpm tor 1 0 minutes as soon as possible aft er collection (within 2 hours) and the plasma transferred 
to PPN tubes and deep trazen (<- 20 oe). 
4.4 Faeces collection 
The amount of faeces trom cages 1, 3 and 5 was weighed daily, diluted with water (about 1:4 w/v) , 
mixed thoroughly and a 50-ml sample was taken and deep frozen at <- 20 oe tor drug analysis. 
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4.5 Sample collection at slaughter 
The broilers were slaughtered in Spelderholt's slaughterhouse immediately after remaval trom the 
cage. During exsanguination of the broilers after electrical stunning, blood was collected trom Vena 
brachiocephalicus (neck vein) directly into heparinised glass tubes, subsequently centrifuged and the 
plasma deep trazen at <- 20 oe. From each broiler all tissues we re collected separately in plastic 
bags (liver, kidney, abdominal fat, breast muscle, skin with adhering fat) to avoid mutual 
contamination. The tissue samples were immediately stared at - 20 oe. 
5 DRUG ANAL YSIS 
5.1 General 
Drug analyses were carried out at the RI KIL T-DLO, Wageningen. 
Qualilalive and quantitative microbiological analysis of flumequine in kidney, liver, skin, muscle tissue 
and selected plasma samples were performed utilising Escherichia co/i Bay 14 as test strain (25). 
The quantitative HPLe determination of flumequine, its 7-hydroxy metabolite, salicylic acid, salicyluric 
acid and gentisic acid was carried by automated sample enrichment HPLe analysis with UV and 
fluorescence detection. 
5.2 General preparation of samples. 
Thawed muscle, kidney, liver and skin were cut in smal! pieces, homogenised with distilled water 
(muscle, kidney and liver: 2:3 w/v; skin: 1 :2) by a stomacher tor 5 minutes and deep trazen again ( <-
20°C}. Befare analysis the samples were thawed, mixed, centrifuged at 5000 rpm tor 10 minutes and 
the supernatants were used tor bioassay and after pre-treatment tor HPLe analysis. Plasma was 
directly used for bioassay or after dilution tor the HPLe determination. 
5.3 Preparation of stock and working solutions 
Stock salution (1 00 pg/ml) of flumequine and 7 -hydroxyflumequine we re pre pa red in amber glassware 
by dissolving 10 mg (corrected tor activity) in 1 oo mi of 0.01 M NaOH. Working solutions we re 
prepared by diluting stock solutions with distilled water. 
Stock solutions (1 000 pg /mi) of salicylic acid, salicyluric acid or gentisic acid were prepared by 
dissolving in distilled water. 
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5.4 Preparatien of standards (calibrators) 
To blank tissues (cut in small pieces) the appropriate werking salution of flumequine, 7-
hydroxyflumequine,salicylic acid, salicyluric acid or gentisic was added, homogenised with distilled 
water in a stomacher and treated as described above (see 2). Appropriate werking solutions of the 
flumequine, salicylic acid and their metabolites were added directly to plasma or diluted faeces. 
The following flumequine standards were prepared (tor bioassay and HPLC): 
0 - 0.156 - 0.312 - 0.625 - 1.25 - 2.50 - 5.0 - 10.0 pg/ml tissue homogenate or mi plasma. 
Fortheether drugs the following standards were prepared (used in HPLC analysis): 
7-hydroxyflumequine : 0.10 and 0.20 pg/ml or g tissue 
salicylic acid : 1 - 5 - 1 o - 50 pg/g tissue or mi 
salicyluric acid 
gentisic acid 
5.5 Bioassay 
Performance of the bioassay 
: 0.1 - 1 and 1 0 pg/ml or g tissue 
: 0.1 - 1 and 1 0 pg/ml or g tissue. 
An agar ditfusion methad was used utilising Escherichia co/i Bay 14 and large glass plates (30x30 
cm). 
Autoclaved Standard 11 Nähragar (Merck 7881), supplemented with 0.1 % KH2P04, was caoled to 
50°C, inoculated with 0.1 mi of 1 0-fold diluted 24-h incubated E. co/i Brain Heart lnfusion culture ( 
about 105 c.f.u./ml agar), the agar adjusted to pH 6.0 and poured out into the plates. The agar depth 
was 2.0 mm and after solidification, holes of 9 mm (for plasma analysis) or 14 mm (tissue analysis) 
we re punched out of the agar. Subsequently the punch-holes were tilled with 1 00 pi of plasma or 250 
pi of supernatant (tissues) in duplicate for calibrators and samples. The plates were covered with filter 
paper and a glass plate and incubated overnight (about 18 h) at 37 °C. The inhibition zones were 
measured twice (diagonal) with a callipers to the nearest 0.1 mm and the concentrations calculated. 
Ca/cu/ations 
The calculations were carried out according curve statistics by means of unweighted regression 
analysis. The line model used was: Y ;::: b.lnX + a, where 
Y ;::: inhibition zone 
X ;::: antibictic concentrations 
a ;::: intercept 
b;::: slope 
The correlation coefficients of the curves used, exceeded 0.99. 
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5.6 HPLC analysis 
Reagents 
All chemieals were of analytica! grade (Merck, Darmstadt, Germany). The HPLC eluent was prepared 
by mixing 660 mi 0.02 M o-phosphoric acid, 200 mi acetonitrile and 140 mi tetrahydrofuran. The eluent 
was filtered and degassed befare use. A 0.001 M o-phosphoric acid salution was prepared tor flushing 
the on-line Serdolit AD-4 concentration column. Befare use, this salution was passed through a 
chromatographic column (10x 2 cm) tilled with amberlite XAD-2 material 0.3-0.78 mm (BDH, UK). 
Jnstrumentation and chromatographic conditions 
The column-switching HPLC system consisled of an automatic sampler model Gilson 232-401 (Gilson 
Medica! Electronics, Villiers-fe Bel, France) equipped with one extra dilutor 401, a sixport switching 
valve as injection part and a sixport switching valve incorporated with the enrichment column , one 
liquid chromatographic pump capable of maintaining pulseless flow rates of 0.1 · 9.9 mi/min (Model 
6000A, Millipore, Milford, USA), a fluorescence detector model Hitachi F 1050 (Merck) and a Kratos 
Spectraflow 783 UV detector (Separations, Hendrik I do Ambacht, Netherlands). The analytica! column 
was a 150 x 4.1 mm ID PRP-1 10 pm column (Hamilton, Reno, USA) and the pre-concentration column 
(1 0 x 2.1 ID mm) was packed with Serdolit AD-4 0.05-0.1 mm (Serva, Heidel berg, Germany). 
The eluent flow was 1 mi/min and the sample enrichment flow 0.36 mi/min. The fluorescence detector 
operated at an excitation wavelength of 315 nm and an emission wavelength of 360 nm; UV detection 
was carried out at 320 or 237 nm. Plasma samples were mainly chromatographed with UV-detection 
at 320 nm. For analysis of the other matrices both fluorescence and UV-detection at 237 nm were 
used. An injection loop of 1 00 pi was used. The time event sequence tor sample enrichment and 
separation was: 0 min, injection; start flushing the concentration column with 2 mi 0.001 M o-
phosphoric acid; 5.5 min., activate six-port valve tor 7 min backflushing the components of interest 
to analytica! column; 6.5 min, reset six-port valve and equilibrate the concentration column with 2 mi 
flushing solvent; 20 min, next injection. 
Sample preparation tor HPLC 
a) Direct HPLC analysis 
Plasma samples and standards were thawed; 100 or 200 pi were diluted to 1 mi with distilled water. 
The mixture was centrifuged at 10,000 rpm tor 10 minutes and the supernatant was pipetted into a 
reaction vial tor the autosampler. An aliquot was injected into the HPLC system as described (6.3.2). 
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The supernatant (see 2} of the tissue samples were prepared as follows: 
Musc/e: homogenales were centrifuged at 10,000 rpm tor 20 minutes and an aliquot of the 
supernatants were directly injected into the HPLe system. 
Liver and kidney: to 1500 JJI of supernatant 300 JJI 0.5M perchloric acid was added, centrifuged at 
13,000 rpm. The supernatant was pipetted into an autosampler vialand an an aliquot injected into the 
HPLe system. 
Skin: homogenates were centrifuged at 10,000 rpm tor 10 min. The supernatants of skin were filtered 
through an AcrodiscR filter (0.45 micron; Gelman Sciences, Mi., USA; art no.4217} into an autosampler 
vial and an aliquot was injected into the HPLe system. 
Fat: to 2 g of fat 10 mi of hexane was added, rotated tor 1 h (30 rpm), 10 mi of distilled water was 
added, rotated again tor 1 h. To separate phases the tube was centrifuged at 5000 rpm tor 10 
minutes. The lower aqueous phase was transferred to an autosampler vial and an aliquot was injected 
into the HPLe system. 
Faeces: faeces homogenates were centrifuged and the supernatants were diluted 1 00 times with 
distilled water. Aft er centrifugation at 5000 rpm tor 1 o minutes, the supernatants we re transferred to 
an autosampler vial and injected into the HPLe system. 
b} Deconjugation of the samples 
Two types of 13-glucuronidase preparations (concentration 10,000 Fishman lU/mi), namely Escherichia 
coli Type IX-A (Sigma no. G-7396 ) and another one containing both 10,000 Fishman lU beta-
glucuronidase and 1 o,ooo Ray lU arylsulfatase/ml (IBF Biotechnics, France), were used. 
Plasma 
To a volume of 100 JJI plasma, 100 JJI of 13-glucuronidase (E.coli} and 900 JJI of distilled water were 
added, incubated overnight at 37 oe, centrifuged at 10,000 rpm and the supernatant injected into the 
HPLe system. For selected plasma samples, deglucuronidation was repeated with the mixture of beta-
glucuronidase/arylsulfatase at pH 5.0. 
Faeces 
To 1 mi of faeces supernatant 0.5 mi sodium phosphate buffer (0.1 M pH 5.0} and 0.5 mi beta-
glucuronidase/arylsulfatase (IBF) salution were added, incubated overnight at 37 oe, diluted 50 times 
with distilled water and injected into the HPLe system. 
c) ealculations 
Peak heights of flumequine, salicylic acid ortheir metabolites we re obtained trom the output generated 
by two recorder systems. eaUbration curve analysis was performed according curve stalistics by 
means of linear least-square regression analysis (with the line toreed through the origin) of the peak 
heights tor the standards. 
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The line model used was Y = b.X, where 
Y = peak height 
X = drug concentratien 
b = slope 
For acceptance of the line, the correlation coefficient must exceed 0.99. 
6 RESUL TS AND DISCUSSION 
6.1 Experimental animal phase 
The data about mean daily water consumption and the daily drug intake per kg body weight are 
presenled in table 1. 
Co-medication of sodium salicylale did nat clearly affect the daily water consumption or animal 
behaviour. The number of broilers removed (drop-outs) tor group A, 8 and C was respectively 1, 2 and 
3. In groups A and C one broiler died the first day of medicatien (no.1 OA and 36C), no. 32C was 
somnolent (airsacculitis) during the whole medicatien period (no water and food intake) and died at 
day 6 of medication. At day 3 of medicatien broiler no. 29C became leg weakness; at day 7 no. 198, 
228, and 29C were somnolent and no. 29C died at day 8 of medication. At necropsy broiler 228 had 
livercirrhosis; the cause of dead tor the broilers removed could nat be related to drug treatment. 
The flumequine analysis of the water samples pointed out, that its real concentratien was 81 % of the 
expected one and the calculated (actual) mean daily intake is corrected accordingly. The average 
dosage of flumequine tor the 3 groups was 9.3 mg/kg/day. 
Table 1 
Drinking water and drug intake of the broilers 
Group Number Mean water intake (*) Flumequine 
ml/kg/day mg/kg/day(**) 
A 12 114.1 9.2 
(27.8) ... (2.3) 
8 12 126.2 10.2 
(26.6) (2.2) 
c 12 105.8 8.6 
(26.6) (2.2) 
(*) corrected tor removed broilers 
(**) actual dosage (corrected according to flumequine water concentrations). 
(***) in brackets standard deviation. 
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Salicylale 
mg/kg/day 
0 
31.5 
(6.7) 
265.0 
(66.5) 
6.2 Assay methodology 
General aspects 
The scope of this study was nat to reach the lowest limit of quantification ar to validate tor each drug 
ar metabolite the HPLC methods pertormed, in extenso. Primarily the target drugs to be quantified, 
were flumequine and its 7-hydroxy metabolite. But during flumequine analysis of plasma samples, it 
became obvious however, that sodium salicylale and salicyluric acid could be determined 
simultaneously. Flumequine and its metabolite could be quantified by utilising UV-detection at 320 nm 
as well as with fluorescence dateetion (see fig. 3}. With UV-detection at 320 nm as well as with 
fluorescence detection, gentisic acid could intertere slightly with 7-hydroxyflumequine analysis 
(difference in retentien times about 0.8 minutes). With UV-detection at 237 nm salicylale and its 
metabolites could be chromatographed without interterenee with flumequine and its 7-hydroxy 
metabolite, but matrix components intertsred with the salicylale analysis. Utilising UV-detection at 237 
nm the presence of gentisic acid could be proven (na interterenee with 7-hydroxyflumequine) and 
therefore bath fluorescence and UV-detection at 237 nm were used tor quantification of flumequine, 
salicylale and their metabolites. Plasma analysis was mainly pertormed with UV-detection at 320 nm, 
and the other matrices were analysed with fluorescence and UV-detection at 237 nm. 
Linearity, recovery and limit of quantification. 
The calibration curves of the spiked standards were linear in the range tested and revealed correlation 
coefficients > 0.99. The limit of quantification (LOQ) tor the drugs, defined as six times the noise level 
tor blanc samples, and the mean recovery percentage are presented in table 2. 
Reproducibility. 
Data about reproducibility were obtained tor plasma samples. Analysis of quality control samples 
(spiked at the level of 1 pg/ml}, which were incorporated in the various plasma runs, revealed a 
coefficient of variatien (=CV) of 6.7% (n=25}. Since no glucuronides were observed tor flumequine 
ar its metabolites, the data obtained after deglucuronidation can be considered as replicatas of the 
first analysis. Taking this into account tor group A it would reveal a CV tor flumequine of 9.6% (n=73}, 
tor 7-hydroxyflumequine of 11.5 % (n=63} and torsodium salicylale of 9.3% (n=41}. 
I - =1 
Fig.3 
Representative chromatagram of a plasma sample (broiler no.28/4) 
containing per mi 0.096 pg 7-hydroxyflumequine (peak 1), 0.74 pg 
f/umequine (peak 2) and 62 pg sodium salicylare (peak 3). 
UV defection at 320 nm. 
Table 2 Mean recoveries and limit of quantification of flumequine, sodium salicylate and their 
metabolites tor various matrices 
Drug Flumequine 7-Hydroxy Sodium Salicyluric Gentisic 
Matrix 7-hydroxy salicylate acid acid 
Plasma 
Recovery % 98.2 100 51.4 76.5 43.4 
LOQ (tig/mi) 0.01 O(a) 0.006(a) 1 (a) 0.5(a) 0.5(a) 
Muscle 
Recovery % 27.9 58.2 56.8 66.3 13.2 
LOQ (tig/g} 0.030(b) 0.005(b} 0.6(b) 0.5(b) 2(c) 
Kidney 
Recovery % 50.0 47.3 35.1 57.9 16.8 
LOQ (tig/g) 0.050(b) 0.030(b) 2(b) 0.5(b) 2(c) 
Liver 
Recovery % 51.2 45.6 39.5 68.9 15.3 
LOQ (tig/g) 0.050(b) 0.030(b} 1 (c) 0.5(c) 2(c) 
Skin 
Recovery % 81.1 92.5 55.4 86.0 29.8 
LOQ (tig/g} 0.030(b} 0.01 O(b) 3(c) 0.5(c) 2(c) 
Fat 
Recovery% 65.5 94.8 78.1 90.0 89.0 
LOQ (tig/g} 0.030(b) 0.01 O(b} 5(c) 1 (c) 1 (c) 
(a) UV-detection at 320 nm; (b) fluorescence dateetion (c) UV -detection at 237 nm 
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Matrix interterenee 
In the quantification of flumequine in plasma, muscle, organs, fat and skin, matrix interterences 
occurred, when fluorescence detection was used ,corresponding to 10 - 30 ppb flumequine. 
Flumequine plasma analysis with UV-detection at 320 nm revealed no matrix interterence. In the 
analysis of sodium salicylate and its metabolites in plasma, organs, skin, fat and faeces, endogeneaus 
components intertsred in case of fluorescence or UV-detection at 320 nm. Salicylate plasma analysis 
with UV-detection at 320 nm resulted in no matrix interterence. Further optimalisation of the HPLC 
methods tor salicylale and flumequine analysis in various tissues would be desirable. 
6.3 Plasma pharmacokinetics of flumequine and sodium salicylate 
6.3. 1 General aspects 
In the plasma samples of the brallers, no indication tor the pressnee of glucuronide or sulfata 
conjugates of flumequine, its 7 -hydroxy metabolite, sodium salicylate, salicyluric acid and gentisic acid 
was found. For that purpose two types of beta-gluronidase were used on selected plasma samples 
trom group A, B and C. 
6.3.2 Flumequine 
a) Pharmacokinetic aspects 
The plasma concentrations (mean ± standard deviation) of flumequine and its 7-hydroxy metabolite 
obtained in group A, B and C are presented in table 3 and graphically in Figs. 4, 5 and 6. 
Following oral drinking water medicatien of about 9.3 mg/kg/day a steady state level (about 0.9 ,ug/ml) 
of flumequine was obtained within one day tor all groups. The 7-hydroxyflumequine (metabolite) 
plasma concentratien in all groups was about 1 0 % of that of the parent drug. 
After cessation of the medication, a tast deelins in plasma drug concentrations of flumequine and its 
metabolite was observed. 
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Selected pharmacokinetic parameters obtained tor flumequine in the present study and that of Atev 
{2) are summarised in the table below. 
Group 
Number of broi lers 
Flumequine(a) mg/kg 
+ salicylate mg/kg 
Mode of administration 
A 
6 
46.79(64.98) 
0 
Oral 
B 
6 
52.34(72 .70) 
224.5 
Oral 
c 
4 
44 .12(61. 28) 
1888.3 
Oral 
Atef(2) 
10 
12 
0 
Int ravenous 
Cl 8 • 1/h/kg 
VP. . 1 /kg 
T~ . h 
0.334 ± 0.098 
2.76 ± 0.69 
6.32 ± 2.98 
9.12 ± 4.31 
0.341 ± 0.092 
2.65 ± 0.66 
5. 43 ± 0.38 
7.83 ± 0.55 
0.304 ± 0. 112 
2.10 ± 0.78 
4.82 ± 0.70 
6. 95 ± 1. 00 
0 . 385 ± 0 . 0 11 
2. 63 ± 0.10 
4.94 ± 0.15 
f·1RT. h 
(a) For group A.B and C the absorbed dosage in 171 h is corrected for t he bioavailability. According to Atev (2) is that 72% of the actual dose (given in brackets) . 
Analysis of varianee utilising an unpaired nonparametrie (Mann-Whitney) two sample test revealed that 
the pharmacokinetic parameters did not ditter significantly between group A, B and C and close to 
those reported by Atef (2) tor flumequine after intraveneus administration. The disposition half-lives 
tound in this study are at the same magnitude as those reported by Atev et al. {2) and Chevalier et 
al {6) after a single oral dose. 
Table 3 
Flumequine concentrations (determined by HPLC) i n p l asma of chickens aft er water medicatien during 8 d ays. 
(data of non- d egluc u ronidated samples are o n ly presented as no gluc uronide conjugates were found) 
Hours 0 3 6 27 51 75 147 171 2 3.5 6 24 
Drug Concen tratiens i n Jjg/ ml p l asma (mea n ± s.d.) 
Group A (n=12 ) 
Flume~ine 
t-lean 0 0.21 0.50 0.96 1. 03 0.95 1 .06 0.90 0.75 0.57 0.40 0 .08 
s.o. 0.11 0. 17 0.30 0.28 0.28 0.52 0.36 0.37 0.26 0.22 0 . 10 
n=6 n=4 n =6 n=6 n=6 
7-hydroxyflume~ine 
~1ean 0 0.020 0 . 082 0.099 0.10 0.11 0. 11 0.089 0.080 0.075 0. 071 
s . d. 0.010 0.022 0 . 018 0. 0 11 0 . 034 0.042 0.023 0.028 0.019 0.01 0 (<0.005) 
(n=9 ) n =6 n=4 n =6 n=6 n =6 
Group 8 (n=12 ) 
Flume~ine 
Mean 0 0.55 0 .65 1. 01 0 .84 0.96 0.94 0.89 0.82 0 . 49 0.29 0.06 
s.o. 0.24 0 . 19 0.28 0. 20 0 .29 0.46 0.41 0.27 0 .20 0.10 0.02 
n =11 n=6 n =4 n=6 n=6 n =6 
7 -hydro~flume~ine 
f·1ean 0 0.050 0 . 077 0.088 0.077 0.087 0.098 0.099 0.095 0.066 0 .048 
s.d. 0.016 0.023 0.025 0.020 0.022 0.032 0.037 0. 041 0.01 3 0.004 ( <0.005) 
n=11 n =6 n=4 n =6 n=6 n =6 
Gr oup C (n=9) 
Flumeguine 
~1ean 0 0.35 0.44 0.77 0.76 0.92 0.66 0.90 0 . 43 0.60 0.32 0.04 
s.o. 0.16 0 . 26 0.31 0.24 0. 32 0.42 0.30 0.09 0.22 0.13 0 . 04 
n=8 n=4 n =5 n=4 n =4 n=4 
7 - hydroxyflume~ine 
t-lean 0 0.042 0.065 0.081 0. 077 0 . 092 0.088 0.091 0.070 0.073 0 .046 
s.d. 0.015 0.032 0.036 0.022 0.035 0.039 0.034 0.020 0.018 0.01 3 (<0.005) 
n• 8 n •8 n =4 n=5 n =4 n=4 n •4 
aft er start of medication; •• • after cessation of med1cat 1on 
Dosage: 
Group A 9 . 2 mg flumequine/kg/day 
Group 8 10.2 mg flumequi ne + 31.5 mg sodium sal i c yla t e/kg/day. 
Group C 8.6 mg flumequine + 265 .0 mg sodium salicyl a t e/kg/day. 
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Fig. 4 Pharmacokinetic profiles of flumequine and its 7-hydroxy metabolite in plasma of broilers (n= 12) 
fol/owing drinking water medication of 9.2 mg f/umequine/kg/day during 171 hours. 
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Fig. 5 Pharmacokinetic profiles of f/umequine and its 7-hydroxy metabolite in plasma of brai/ers (n=::; 12} 
following drinking water medication of 10.2 mg f/umequine + 31.5 mg sodium sa/icylate/kg/day during 171 
hours. 
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Fig. 6 Pharmacokinetic profiles of f/umequine and its 7-hydroxy metabolite in plasma of broilers (n=9) 
fol/owing drinking water medication of 8.6 mg f/umequine + 265 mg sodium salicylate/kg/day during 171 
hours. 
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Following a single oral dose of 12 mg/kg the maximum flumequine plasma concentrations of about 3 pg/ml 
were obtained about 2-3 hours after administration (2,6,25). These flumequine plasma concentrations are 3 
times higher than these obtained in this study after a continuous administration of flumequine in drinking 
water. In our study the practical mode of administration is performed. The eliminatien half-lives reported in 
the above-mentioned studies are of the same magnitude as these in this study. 
b) Comparison of flumequine concentrations in plasma samples determined by HPLC and bioassay. 
In table 3 the mean flumequine plasma concentratien data are presented, which were determined by HPLC 
and bioassay. Comparison of the data obtained with bath methods by linear regression, Y =B.X (V= HPLC, 
X = Bioassay), revealed that there was a good correlation between the concentration data obtained with the 
two methods (r= 0.97; n=63). Performance of a paired t test resulted in a P value of 0.23 (no significant 
ditterenee between the bioassay and HPLC data). Considering the HPLC and bioassay concentration data 
as replicates, the CV tor ditterenee was 1 0.4 % and lies within the 15 % acceptance I i mits tor replicate 
analysis at this level (EC guideline). Based on these results it can be concluded that the HPLC and bioassay 
data were similar. In fig. 7 both sets of data are related in a visual way. lt should be kept in mind, that the 
microbiological activity of the 7-hydroxyflumequine is about 25 % of those of flumequine. As the hydroxy 
metabolite concentrat ion in plasma was about 1 0% of the parent drug, its contri bution to the antimicrobi-
ological activity of plasma samples is negligible. 
24 
l .96 
H 
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c 
Fig. 7. Gorre/ation between flumequine plasma concentrations determined microbiological/y as wel/ as by 
HPLC (n=63; r = 0.97) . 
Correlation Bioassay uice HPLC fluroequine plasroa concentrations 
• • 
• 
• • 
• 
Bioassay 
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6.3.3 Sodium salicylale 
Sodium salicylate plasma concentrations (mean ± s.d.) are given in table 4 and depicted graphically in fig. 
8. Following drinking water medicatien of 31 .5 mg sodium salicylate/kg/day (group B) a salicylate plasma 
steady state level of a bout 1 0 pg/ml was observed. A dosage of 265 mg salicylate/kg/day in group C (8.4-fold 
higher dosage than in group B) resulted in a salicylale steady state level of about 50 pg/ml plasma. lt is 
generally assumed that salicylate has analgesie activity at plasma levels exceeding 50 pg/ml (14) . So to 
broilers a very high dosage of salicylate has to be administered to obtain an analgesically effective level. 
After cessation of the medicatien the salicylale disappeared tast trom the plasma; in group C (high dose 
level) the drug concentrations in plasma were below the LOQ within 6 h after medication. A rough estimation 
of the salicylate disposition half-life in broilers would be less than 2.5 h. 
Comparison of the plasma concentrations obtained in this study tothese in ether species (man,rabbits, dogs) 
reveals a 1 0-fold lower sodium salicylate plasma concentratien in broilers at similar dose levels than in ether 
species(13,14,15,26,27,28,31). An explanation may be a very tast eliminatien ( = metabolism + excretion) as 
seen tor ether drugs (1 0,21 ,23). 
Tabl e 4 
Sodium salicylate concentl·ations in plasma of chickens after water medication during 8 days. 
Hours 0 6 27 S1 7S 147 171 2 3.S 6 24 
Drug concentrations i n 119/ml plasma (mean i: s.d.) 
Group B 
~lean - 0 <O.S 10 .1 10 .1 6.9 
s .d . 2.9 3.7 3.0 
n=10 n~1o n=9 
Group c 
r~ean - 0 76 ss S1 51 
s.o. 54 23 24 26 
n=9 n=9 n=9 n=9 
l·lean + 0 65 ss S3 49 
s.d. 53 25 26 28 
n• 8 n=8 n•8 n=8 
- or + = without or with deglucur onidation 
• • after start of medication 
•• = after cessation of medication 
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8.9 
3.9 
n=9 
36 
22 
n=8 
35 
26 
n=8 
10 . 9 10.0 <1 <1 <1 
s.o 6.2 
n=8 n=S 
49 12.9 18.5 <1 <1 
17 7.8 8.7 
n•4 n=S n=4 
56 19.1 
21 5.2 
n=3 n=3 
Dosage: 
Group B: 31.5 mg sodium salicylate/kg/day 
Group C: 265.0 mg sodium salicyl ate/kg/day 
Fig 8. Sodium salicylale plasma concentrations (mean ± s.d.) fo/lowing drinking water medication of 31 .5 
mg/kg/day (group 8) or 265 mg/kg/day (group C) during 171 h. 
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6.4 Residue aspects 
6.4.1 Flumequine 
a)Residues 
The flumequine concentrations in kidney, liver, muscle, skin (determined by HPLC and bioassay, and 
corrected tor recovery), plasma and fat (HPLC data) are detailed in table 5; in table 6 the mean (±s.d.) 
concentrations of flumequine and its 7 -hydroxy metabolite concentrations are presented. 
At 2 hours after medication the highest tissue flumequine concentrations were observed in the kidney (mean 
concentration range: 1.25 to 2.12 pg/g), foliowed by liver, plasma, muscle, skin and fat in decreasing order. 
The 7-hydroxyflumequine metabolite concentration was also the highest in the kidney (mean concentrations: 
0.57 -0.72 pg/g), foliowed by skin, liverand plasma. In muscle the mean 7-hydroxy metabolite con centration 
was below 0.05 pg/g tissue(less than 6% of that of the parent drug) and in fat tissue this metabolite was not 
quantifiable (LOQ: 0.01 pg/g). 
At 24 h after medication the highest tissue flumequine concentrations were found in liver and skin; their 
means ranged between 0.052 and 0.17 pg/g tissue. At this time, the tlumequine concentrations in the muscle 
we re below 0.10 pg/g tissue except in chickans no.1 and 5. At 24 h aft er medication low concentrations of 
the 7-hydroxy metabolite could be quantified in kidney and skin, whereas in plasma, muscle, liver (and fat) 
lts concentration was below the LOQ. Although the residue data presented by Atef et al (2) and Samaha et 
al (25) are not camparabie to those in this study (no skin residues; different mode of administration), their 
data showed that at 24 - 36 h after medication all tlumequine residues had disappeared trom edible tissues. 
Unfortunately no residue data tor skin were reported. 
Table 7 presents the concentration ratio's of tissues versus plasma. A signiticantly lower muscle versus 
plasma concentration ratio was observed in group C ( co-medication of the high salicylate dose level) than 
in groups A (no co-medication) and B (low salicylate co-medication). An increase of the concentration ratla's 
tor liver, muscle and fat was observed at 24 h compared to those at 2 h drug withdrawal, indicating a langer 
persistenee (retention) of flumequine in the above-mentioned tissues. The persistenee in liver may be due 
to a tirst-pass effect due to prolonged absorption trom the gastro-intestinal tract or to entero-hepatic 
recirculation of flumequine. The langer persistenee in muscle and fat may be related to a slow back ditfusion 
of flumequine trom these tissues to the vascular blood system or to binding tospeeltic components (?). 
In liver a significantly relative lower 7-hydroxyflumequine concentration was present in the salicylale co-
medicated groups at 2 hours after cessation of the medication. The flumequine versus 7-hydroxyflumequine 
concentration ratio's in liver were: 
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Group A: 14.5 ± 4.2 (n=4); group B: 4.57 ± 1.60 (n=4); group C: 5.38 ± 2.45(n=5). 
The P values (unpaired Mann-Whitney two sample test) were tor A versus B: 0.029; tor A versus C: 0.0045 
and B was not significant trom C. 
The flumequine versus 7 -hydroxyflumequine concent ration ratio's in kidney samples of group A and B differed 
significantly trom those trom group C; the ratio's were: 
Group A: 3.37 ± 1.23 (n=4); group B: 3.37 ± 1.22 (n=4) and group C: 1.79 ± 0.32 (n=4). (P values A versus 
C: 0.032; B versus C: 0.057 (=marginally significant). 
b) Gomparisen of HPLC and Bioassay data. 
A discrepancy was observed between the tissue concentratien data in muscle, liver and kidney determined 
by bioassay versus HPLC, whereas tor plasmaand skin a close agreement was seen. The bioassay data tor 
kidney, liver and muscle were in general much higher than those obtained by HPLC. The bioassay versus 
HPLC concent ration ratio's were tor muscle: 1 .86±0.47 (n=B), tor liver: 1.63 ± 0.36 (n= 15) and tor kidney: 
1.95 ± 0.60 (n= 16). lt has to be stressed that the same standards were used tor bioassay and HPLC. An 
explanation may be that an (as yet) unknown microbiological active metabolite is present in these tissues, 
which was nat quantified by HPLC (see section about metabolism). 
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Table 5 
FLffiolEQUINE CONCENTRATIONS (f.IEASURED BY HPLC AND 8IOASSAY) IN PLASt•IA AND TISSUES OF CHICKENS AFTER 
DRINK \•lATER t·lEDICATION (average dosage 9.3 mg flumequine/kg/day). 
FLUI·1EQUINE CONCENTRAT !ONS IN 1!.919 TI SSUE OR t·!L f·luscle Riane:t Liver Sl<1n Fat Plasma 
No. Bio HPLC 810 HPLC Bio RPLC Bio HP[C HPCC HPLC 
Al 0.161 0.8S 0.2S 0.49 0.25 0.43 0 .50 0 . 16 
A2 0.046 0.13 0.12 0.01 
A3 0.053 0.12 0.097 0.02 
A4 (0. 029) . 0.11 0.097 0.01 
AS 0.136 1. 80 0.65 0.49 0.30 0.24 0.058 0 . 26 
A6 0.035 0.12 0.09 0 . 04 
A7 1. 53 1. 06 4.88 3. 08 2. 18 1. 47 1. os 0.81 0.21 1. 23 
AS 0 .96 0 .4S 3.10 1. so 1.10 0.76 0.90 0.67 0 .1S o.so 
A9 1. 21 0.98 3.10 2.0S 1. 6S 0.87 0.60 0.51 0 .14 o.ss 
All 0 .27 1. 70 1.10 0.5S 0.51 0.30 0.27 0.11 0 .43 
Al2** 0.03S 0.17 0.33 0.38 0 . 049 0 .02 
813 0.063 0.1S 0.090 0.08 
814 0 . 066 0.40 0.33 0 . 18 0.14 0 . 10 
81S 0.038 0.16 0.16 0.07 
816 (0. 029) - 0.15 0.096 0.04 
817 (0. 010) - 0.16 0 . 093 0.04 
818 0.044 0. 13 0.082 0.04 
820 1.16 O.S3 4.40 2.S8 2.08 1. 09 0 . 84 0.6S 0.17 1. 03 
( 821 1.13 0 .82 3.78 2.58 1. 90 1.13 0.60 0 . 48 0.16 1. 01 822** (0 . 029) - 0 .10 0.092 0.07 
823 0.82 0.48 3.78 1. 98 1. 73 0 . 80 O.Sl 0.37 0 . 11 0.82 
824 O. S4 0.23 2.S2 1. 35 1. 10 0.49 0.28 0 . 2S 0 . 071 0 . 4S 
C2S 0.057 0.3S 0.2 1 O.OS8 0.09 
C26 0.041 0.14 0.047 0. 07 
C27 (0 .021) - 0.12 o.oss 0.02 
C28 (0. 018) - 0.10 0. 04S 0.01 
C30 0 .19 2.63 0.93 0 . 63 0 .47 0.27 0 . 23 0 .07S 0.41 
C31 0.048 1. ss 1. 1S 0.43 0 .44 0.21 0.23 O.OS4 0.32 
C33 0.13 2. 3S 1. 33 0 .90 0.63 0.20 0.13 0.36 
C34 0.67 0.28 2.93 1. 33 1. 38 0. 72 0.27 0 . 26 O.S2 
C3S 0 . 14 3 . 08 1. 50 1.30 0.7S 0 . 69 0.50 0.097 O. S2 
<0.60 <0.03 <0.2S <O .OS <0.40 <O.OS <0.20 <0.030 <0.040 <0 . 01 1'919 
concentrations below limit of quantification are in brackets. 
** outliers (see detailed plasma concentrations i n Appendix) 
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Table 6 
~1EAN DRUG CONCENTRATIONS (/tg/ml or g tissue) IN PLASMA AND EDIBLE TISSUES OF CHI CKENS AFTER HATER 
~1EDICATION OF FLUNEQUINE (average dosage 9.3 mg flumequine/kg/day) 
Time Kidney Liver l·1uscle Plasma Skin Fat 
(a) n Flum . 7-hydr. Fl um . 7-hydr Flum 7-hydr Flum 7-hydr Flum 7-hydr Flum 
Group A 
2 4 1.93 0.57 0.90 0.066 0.69 0. 041 0.75 0.080 0.57 0.18 0.15 (0. 86). (0.13) (0 .41) (0.037) (0. 39) (0.019) (0.37) (0.028) (0. 23) (0 . 076) (0.042) 
Bioassay 3.2 1. 37 1. 21 x 0. 71 n~4 
(1. 3) (0.70) 0.29 (0.33) 
n~3 
24 6 <0.18 0.062 0.17 <0.03 0.077 <0.005 0.08 <0.006 0.19 0.10 0. 092 
(0. 24) (0. 041) (0.08) (0. 057) (0 .10) (0 .16) (0. 09) (0.022) 
Group B n~5 
2 4 2.12 0. 72 0.88 0.22 0.52 0.031 0.82 0.095 0.44 0.21 0.13 
(0. 59) (0.34) (0. 30) (0.10) 0.24 0.017 (0 .27) (0. 041) (0 .17) (0.11) (0. 046) 
Bioasssay 3.62 1. 70 0 . 91 x 0.56 
(0. 79) (0. 43) (0. 29) (0. 23) 
24 6 <0. 096 0.069 0.16 <0.03 0.042 <0.005 0.06 <0.006 0.11 0.067 0.11 
(0 .11) (0.026) (0.02) (0.021) (0 . 02) (0.032) (0.034) (0.032) 
Group C 
n 
x 
2 5 1. 25 0.70 0.60 0.14 0.16? 0.029 0. 43 
(0. 22) (0.18) (0 .14) (0.07) (0.085) 0.008 (0.09) 
Bioassay 2.51 0.93 x 
0.6 1 0.41 
24 4 <0.05 0.039 0.14 <0.03 0.034 <0.005 0. 04 
(0.012) (0.05) (0. 018) (0.04) 
- Hours after cessat i on of medicatien 
number of chickens 
in brackets standard deviation 
not performed 
Table 7 
Tissue vice plasma concentrat ion ratio' s for flumequine in broilers. 
(based on individual data) 
Tissue/plasma Group A Group B Group c 
ratio 
2 hours (*) 
Kidney 2.62 i 0 . 26 2.62 t 0.27 3.00 t 0.63 
(n~4) (n=4) (n~5l 
Liver 1. 23 t 0 . 21 1. 06 t 0.067 1.42 ± 0.22 
(n~4) (n~4l (n=5) 
muscle 0.89 t 0.22 0.61 t 0.14 0.36 t 0.15 
(n~4) (n~4) (n= 5 ) 
Skin 0.81 ± 0.36 0. 55 ± 0.082 0.66 ± 0.19 
(n~4) (n~4) (n~5) 
Fat 0.22 i 0 . 068 0.15 ± 0.017 0.23 t 0 .090 
(n=4) (n~4) (n~4 l 
24 hours(*) 
Liver 5.96 ± 5.02 2 . 83 t 0.96 5.08 t 3.75 
(n=6) (n~4) (n~4) 
~1uscle 2.31 t 1. 66 0.76 i 0.21 1. 01 t 0.56 
(n=5) (n~5) (n~4) 
Fat 5.80 i 4.96 1. 93 t 0.54 2.18 ±1. 87 
(n~5) (n~6) (n~4) 
(*) Hours after medication 
(a ) Unpair ed Mann-Whitney two sample test(** marginal significance) 
NS~ not significant 
0.035 0.28 0.15 0.089 
(0.01) (0 .12) (0 .10) (0.033) 
0.36 n~4 
0.22 
<0.006 0.052 0.023 0.052 
(0.007) (0.005) (0. 007) 
Difference 
significance(a) 
NS 
B versus c :P= 0.020 
A versus B: P~ 0.057(** ) 
A versus C: P~ 0.016 
B versus C: P~ 0.032 
A versus B: P~ 0.057(**) 
B versus C : P~ 0.029 
NS 
NS 
NS 
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6.4.2 Sodium salicylate 
Neither sodium salicylate residues nor its metabolites could be quantified in edible tissues of chickans at 
2 and 24 h after cessation of medicatien at the dosage of 31 .5 mg sodium salicylate/kg/day (table 8). 
At 2 h after cessation of medicatien residues of sodium salicylate could be quantified in kidney, liver and 
muscle tissue of chickans medicated at the dosage level of 265 mg/kg/day (table 8). In fat and skin tissue 
nosodium salicylate could be quantified (LOQ 3-5 JJ9/g). No metabolites (salicyluric acid and gentisic acid) 
could be detected neither at 2 h nor at 24 h after medication. 
Table 8 
f·lean sodium salicylate concentrations (Jlg/g ) in p lasma and edible t issue of chickens 
a f ter wa t er medicatien of sodium salicylate at two dose levels. 
Time Number Sodium sal icyl ate conce nt r a t ions i n uq/q or ml 
(a ) (b) Kidney Liver Muscle Plasma Skin Fat 
Group B (dose: 31.5 mg/kg/day) 
2 4 
24 6 
Group C (dose:265 mg/kg/day ) 
2 5 18.3 
24 4 
Qua n t i f i cat i on 
limit 
(13 . 7 ) 
8.2 
(3. 6 ) 
n=4 
2 
(a) Time after cessation o f medicatien 
(b ) Number of a nimals 
6.5 Drug mass balance 
1. 92 
(0 .10) 
na3 
1 
12.9 
(7.8) 
n =5 
0.6 1 3 5 11g/g or ml. 
The plasma and tissue residue data showed, that in chickans flumequine could be hydroxylated into 7-
hydroxyflumequine, but that neither glucuronide nor sulfata conjugation of the parent drug ar its metabolite 
could be observed. Also for sodium salicylale na metabolites (salicyluric acid, gentisic acid) could be 
detected in plasma or edible tissues. 
To elucidate the extent of metabolism of flumequine and sodium salicylale the faeces of cage 1 (group A), 
cage 3 (group B) and cage 5 (group C) were collected during and after medication. The results of the 
analyses are summarised in table 9. 
Table 9 
Percentage drug recovery from faeces of chickens following water medi cation . 
Flumequine 
Bio + 
Group A 15.8 10.1' '9.0 21.3 19.7 31.4 x 
(cage 1) 
Group B 16.2 8.3 8. 0 19.0 17.3 27.3 49.9 
(cage 3 ) 
Group C 20.1 10 .5 11. 0 18.6 16.7 29.1 66.6 
(cage 5 ) 
(a) = f l umequine + 7- hydroxyflumequ i ne 
- /+ = without/ with be ta - glucuronidase t reatment 
• = Antimicrobial activity (bioassay ) expressedas f lumequine. 
•• = Percentage of drug administered. 
x = net admi nistered 
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Gent i sic aci d 
x 
17.8 
The data in table 9 show, that about 27-31 % of the administered flumequine (parent drug + hydroxy 
metabolite) could be reeavered trom the faeces. Thus about 70 % of the administered dose could not 
accounted tor, which means that in broilers other metabolic pathways must exist tor flumequine. Based on 
the microbiological data obtained tor kidney, liverand muscle, it must be a metabolite (intermediate) having 
microbiological activity befare being conjugated (and excreted) into a microbiological inactive metabolite, as 
in faeces the microbiological activity corresponds well with the sum of flumequine and its 7-hydroxy 
metabolite activity (the latter having 25% of the flumequine's activity ). A possible metabolic pathway might 
be the oxidation of the methyl group foliowed by conjugation (eg with ornithine?) {5,9,23). 
The drug mass balance for sodium salicylale shows that this drug tor a small part is oxidised into gentisic 
acid. The total recovery of sodium salicylale and its metabolite based on the highest dose level (more 
accurate than the lower one) was high namely 84.4 %. This tigure shows, that in broilers sodium salicylale 
is mainly excreted unchanged and that the main metabolic route is by oxidation (into gentisic acid) without 
conjugation. No conjugation of salicylic acid with glycine (= salicyluric acid) or with glucuronic acid was 
observed neither in plasma, nor tissues or in faeces. lt is theoretically possible that the salicyluric acid was 
deconjugated by the bacterial hydrolytic activity in caecum, colon and faeces as shown in rabbits {27) . 
For sulfadimidine it was shown in laying hens, that one of the main metabolic routes of eliminatien was 
hydroxylation of the pyrimidine side chain. Conjugates {glucuronides) were not detected and 57 % of the 
drug mass balance could not be reeavered {21). All these data indicate that obviously other metabolic 
pathways exist in peultry like conjugation with ornithine {5,23). 
6.6 Drug interactions 
The foregoing data, show that there were no obvious drug interactions between flumequine and sodium 
salicylale following oral co-medication. No interaction was observed at the phase I react ion (oxidation), nor 
at the phase 11 level (conjugation with glucuronic acid or sulfate). With respect to drug elimination, no 
alteratien in disposition half-lives we re observed between flumequine group A versus those co-medicated with 
sodium salicylate. For the drug distribution, it was shown that the broilers medicated with 265 mg salicylate 
I kg/ day revealed a lower flumequine muscle versus plasma concentratien ratio. This feature may indicate, 
that flumequine transport into muscle is blocked by high salicylale concentrations. Intraveneus phar-
macokinetic experiments have to elucidate the basic aspects of this feature. For penicillin it is known that 
salicylic acid bleeks the active transport from the cerebrospinal fluid to blood. An explanation might be, that 
therapeutic plasma levels of salicylale produce a metabolic acidosis induced by increased renal excretion 
of Na+ and K+. Subsequently the transport process of acidic drugs (like flumequine or penicillin) through 
membranes may be diminished due to shortage of these mentioned electrolytes {14). 
Other side affects reported tor salicylale is the lowering of indomethacin, naprexen and te noproten plasma 
concentrations, adverse interactions with warfarin and methotrexate, and antagonism with spirolactone-
induced natriuresis {14). 
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6. 7 Flumequine residue screening in broilers 
A requirement tor a screening methad is, that it should be routinely able to detect in suspected broilers the 
flumequine residues excesding an established maximum residue limit (MAL). The screening methad must 
be cheap, reliable and capable of being pertormed on a large scale in the relatively simply equipped RW 
laboratories. At this moment no MAL tor flumequine is established within the EC. Based on MIC data derived 
trom a gastro-intestinal model, a provisional MAL being tor edible tissues 1.0 pg/g and tor milk 0.25 pg/ml 
was calculated (22). 
The advantage of microbiological methods is, that they are easy to be pertormed on a large scale. So if they 
are sensitive enough with regard to the MAL, they are the first choice tor screening purpose. Recently a 
potential microbiological test methad tor screening on quinolone residues became available. The test system 
utilises as bacterial test strain E.co/i Bay 14 , which is sensitive tor flumequine, enrofloxacin, ciprofloxacin and 
other quinolones (25) . 
In this experiment homogenates of muscle, liver, kidney and skin were tested with both the E.co/i and the 
New Dutch Kidney Test (NOKT) test plates tor the pressnee of antimicrobial activity. On each test plate 
standards (spikes of homologous material) were incorporated. Also extracts trom muscle were made and 
tested on these test plat es. The results of the qualitative test methods are presenled in table 1 o. 
The dateetion limit of the E.co/i test plate (based on spiked samples) is tor muscle tissue about 0.6 pg/g, tor 
kidney 0.25 pg/g, tor liver 0.4 pg/g and tor skin 0.2 pg/g (see also table 5). The dateetion limit of the NOKT 
test plate is 2 til! 3-fold higher than that of the E.coli test plate. Table 1 0 shows, that in the experimental 
muscle samples flumequine concentrations excesding 0.3 pg/g could be detected by the E.coli test. lf broiler 
kidney is used as the target organ tor screening, the flumequine concentrations in muscle would probably 
be below 0.06 pg/g if the E.co/i test is negative tor this organ. In case of liver and skin as target tissues tor 
screening it would corresponds to 0.1 and 0.25 pg/g muscle, respectively. 
Although laborious extraction procedure of muscle resulted in a lower microbiological dateetion limit tor flume-
quine in muscle, the E.co/i test plate gave no uniform results below 0.1 pg/g (false-positives, metabolites, 
bound residues?). With muscle extracts the NOKT plate gave more uniform results, but the test plateis less 
sensitive than the E.coli test plate. 
Routine screening with E.coli test plate tor flumequine residues with the use of bath kidney and liver as the 
target organ of screening, would give reasanabie evidence that the muscle tissue residue level is below 0.1 · 
0.2 pg/g in case the target organs are negative. 
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Table 10 
QUAL I TATIVE TEST RESULTS FOR FLffi.IEQUINE IN TISSUES OF CHICKENS AFTER \•lATER lo!EDICATI ON RELATED TO lTS CONCENTRATI ON 
I N ~ruSCLE TISSUES. 
(do sage 9.3 mg flumequine/kg/day; E.col i and NOKT test plate). 
DI~lETER OF I NHI8ITION ZONES IN l·llol 
Flumell!ine ~luscle Huscle extract Kidn e y Liver Skin 
No. concentrat ion E .coli E.coli .!:!Q!IT_ E.coli !:JQ!IT E.coli !:JQ!IT E.coli lli2lSI (l'g/g). 
Al 0.161 27 21 22 . 5 18.5 20 
A2 0.046 
A3 0.053 
l\4 (0. 029) 
AS 0.136 29.5 27 26.3 18.4 
A6 0.035 
A7 l. 06 26.5 35.5 37 3 1 24 28 23 25 
118 0.45 22.5 33 32 29 1 8 25 25 
A9 0.98 24.5 34 35 29 22 27 22 
All 0.27 33 30 26 2 0 17 
A12 0.035 21 
D13 0.063 19 
814 0 .066 19 
815 0.038 19 
816 (0' 029) 18 
8 1 7 (0.01 ) 17 
8 1 8 0 .044 
820 0. 53 24 36 36 31 21 28 18 25 
821 0.82 24 36 37 30 21 28 20 23 
822 (0.029) 
823 0.48 21 35 37 30 2 0 28 1 8 22 
824 0.23 18 33 33 28 18 26 20 
C25 0.057 18 18 
C26 0' 04 1 16 
C27 ( 0.021) 
C28 0.018 
C30 0.19 29 26 28 23 1 9 
C31 0.048 28 24 26 21 18 
C33 0.13 30 28 27 1 9 24 18 
C34 0 .28 20 32 30 29 19 25 18 
C35 0.14 31 28 29 17 26 24 
HPLC determined; in brackets t he concent rat ions below the limit of quantifica tion (-0' 03 Jlg/g)' 
< 16 mm 
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7 CONCLUSIONS 
- In broilers flumequine is highly metabolised. The main metabolite found in plasma, tissues and faeces was 
7 -hydroxyflumequine. Neither glucuronide nor sulfate conjugates could be detected in plasma or faeces. 
The drug mass balance indicated that about 1 0 % of the dose administered, is excreted as parent drug, 
about 20 % as 7-hydroxyflumequine and that 70 % of the dose could not be recovered. Additional 
metabolic pathways tor flumequine must therefore exist in the broilers. 
- About 18 % of the administered dose of sodium salicylale to broilers was excreted as gentisic acid 
(oxidised metabolite of salicylic acid) and 67 % as parent drug. No other metabolites like glucuronide, 
sulfata or glycine conjugates of sodium salicylale could be detected in plasma or faeces. 
- At a dosage of 9.3 mg/kg/day a steady state flumequine plasma concentration of 0.9 Jlg/ml was obtained. 
After cessation of medication the depletion half-life was about 6.5 h. 
- A salicylale dosage of 31.5 and 265 mg/kg/day revealed a plasma steady state level of about 1 o and 50 
Jlg/ml, respectively. 
- The highest tissue flumequine concentration could be found in kidney, foliowed by liver, plasma, muscle, 
skin and fat in decreasing order. The 7-hydroxy metabolite concentration varled between the tissues, being 
the highest in kidney (30- 50% of that of parent drug), skin, liver, plasmaand muscle (in decreasing order). 
In fat the hydroxy metabolite could not be detected. 
- At 24 hafter cessation of medication, flumequine (and its 7-hydroxy metabolite) were quantifiable in muscle, 
skin, liver,fat and a tew kidneys. At that time the mean flumequine concentrations were below 0.10 Jlg/g 
tissue or mi plasma. 
- Sodium salicylale residues could be quantified in kidney, liver, plasma and muscle (not in fat and skin) at 
2 h after medication of 265 mg/kg/day, but not at 24 h after medication. 
- Flumequine plasma disposition and its tissue residue persistenee in broilers was not affected by co-
medication with sodium salicylate. Sodium salicylale administration apparently blocked the flumequine 
transport into muscle tissue and diminished the extent of hydroxylation of flumequine in kidney and liver. 
- Utilising kidney or liveras target tissue tor flumequine residue screening it may be stated that negative tests 
of these organs with a E.coli test plate, the flumequine concentrat ion in muscle tissue is below 0.10 or 0.20 
Jlg/g, respectively. 
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